Blood Purification Techniques, Inflammatory Mediators and Mortality in COVID-19 Patients
Copyright© 2020 National Research Institute of Tuberculosis and Lung Disease..
BACKGROUND: Inflammatory mediators are an important component in the pathophysiology of the coronavirus disease 2019 (COVID-19). This study aimed to assess the effects of reducing inflammatory mediators using hemoperfusion (HP) and continuous renal replacement therapy (CRRT) on the mortality of patients with COVID-19.
MATERIALS AND METHODS: Twelve patients with confirmed diagnosis of COVID-19 were included. All patients had acute respiratory distress syndrome (ARDS). Patients were divided into three groups, namely, HP, CRRT and HP+CRRT. The primary outcome was mortality and the secondary outcomes were oxygenation and reduction in inflammatory mediators at the end of the study.
RESULTS: Patients were not different at baseline in demographics, inflammatory cytokine levels, and the level of acute phase reactants. Half of the patients (3 out of 6) in the HP+CRRT group survived along with the survival of one patient (1 out of 2) in the HP group. All four patients in the CRRT group died. Serum creatinine (SCr), Interleukin-1 (IL1), Interleukin-6 (IL6), Interleukin-8 (IL8), partial pressure of oxygen (PaO2), O2 saturation (O2 sat), and hemodynamic parameters improved over time in HP+CRRT and CRRT groups, but no significant difference was observed in the HP group (All Ps > 0.05).
CONCLUSION: Combined HP and CRRT demonstrated the best result in terms of mortality, reduction of inflammatory mediators and oxygenation. Further investigations are needed to explore the role of HP+CRRT in COVID-19 patients.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Tanaffos - 19(2020), 4 vom: 21. Dez., Seite 291-299 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hashemian, Seyed Mohammadreza [VerfasserIn] |
|---|
| Themen: |
ARDS |
|---|
| Anmerkungen: |
Date Revised 01.04.2024 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM325110247 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325110247 | ||
| 003 | DE-627 | ||
| 005 | 20240401232207.0 | ||
| 007 | tu | ||
| 008 | 231225s2020 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1359.xml |
| 035 | |a (DE-627)NLM325110247 | ||
| 035 | |a (NLM)33959166 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hashemian, Seyed Mohammadreza |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Blood Purification Techniques, Inflammatory Mediators and Mortality in COVID-19 Patients |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Revised 01.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright© 2020 National Research Institute of Tuberculosis and Lung Disease. | ||
| 520 | |a BACKGROUND: Inflammatory mediators are an important component in the pathophysiology of the coronavirus disease 2019 (COVID-19). This study aimed to assess the effects of reducing inflammatory mediators using hemoperfusion (HP) and continuous renal replacement therapy (CRRT) on the mortality of patients with COVID-19 | ||
| 520 | |a MATERIALS AND METHODS: Twelve patients with confirmed diagnosis of COVID-19 were included. All patients had acute respiratory distress syndrome (ARDS). Patients were divided into three groups, namely, HP, CRRT and HP+CRRT. The primary outcome was mortality and the secondary outcomes were oxygenation and reduction in inflammatory mediators at the end of the study | ||
| 520 | |a RESULTS: Patients were not different at baseline in demographics, inflammatory cytokine levels, and the level of acute phase reactants. Half of the patients (3 out of 6) in the HP+CRRT group survived along with the survival of one patient (1 out of 2) in the HP group. All four patients in the CRRT group died. Serum creatinine (SCr), Interleukin-1 (IL1), Interleukin-6 (IL6), Interleukin-8 (IL8), partial pressure of oxygen (PaO2), O2 saturation (O2 sat), and hemodynamic parameters improved over time in HP+CRRT and CRRT groups, but no significant difference was observed in the HP group (All Ps > 0.05) | ||
| 520 | |a CONCLUSION: Combined HP and CRRT demonstrated the best result in terms of mortality, reduction of inflammatory mediators and oxygenation. Further investigations are needed to explore the role of HP+CRRT in COVID-19 patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ARDS | |
| 650 | 4 | |a Acute respiratory distress syndrome | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Continuous renal replacement therapy | |
| 650 | 4 | |a Coronavirus disease 2019 | |
| 650 | 4 | |a Cytokine | |
| 650 | 4 | |a Hemoperfusion | |
| 650 | 4 | |a Inflammatory marker | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Oxygenation | |
| 700 | 1 | |a Shafigh, Navid |e verfasserin |4 aut | |
| 700 | 1 | |a Afzal, Golnaz |e verfasserin |4 aut | |
| 700 | 1 | |a Jamaati, Hamidreza |e verfasserin |4 aut | |
| 700 | 1 | |a Mortaz, Esmaeil |e verfasserin |4 aut | |
| 700 | 1 | |a Tabarsi, Payam |e verfasserin |4 aut | |
| 700 | 1 | |a Marjani, Majid |e verfasserin |4 aut | |
| 700 | 1 | |a Malekmohammad, Majid |e verfasserin |4 aut | |
| 700 | 1 | |a Dastan, Farzaneh |e verfasserin |4 aut | |
| 700 | 1 | |a Mortazavi, Seyed Mehdi |e verfasserin |4 aut | |
| 700 | 1 | |a Sadr, Makan |e verfasserin |4 aut | |
| 700 | 1 | |a Idani, Esmaeil |e verfasserin |4 aut | |
| 700 | 1 | |a Khoundabi, Batoul |e verfasserin |4 aut | |
| 700 | 1 | |a Mohamadnia, Abdolreza |e verfasserin |4 aut | |
| 700 | 1 | |a Abedini, Atefeh |e verfasserin |4 aut | |
| 700 | 1 | |a Kiani, Arda |e verfasserin |4 aut | |
| 700 | 1 | |a Moniri, Afshin |e verfasserin |4 aut | |
| 700 | 1 | |a Nadji, Seyed Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Yassari, Fatemeh |e verfasserin |4 aut | |
| 700 | 1 | |a Mokhber Dezfuli, Mojtaba |e verfasserin |4 aut | |
| 700 | 1 | |a Pourabdollah, Mihan |e verfasserin |4 aut | |
| 700 | 1 | |a Varahram, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Eshaghi, Faezeh |e verfasserin |4 aut | |
| 700 | 1 | |a Malekpour, Mahdi |e verfasserin |4 aut | |
| 700 | 1 | |a Velayati, Aliakbar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Tanaffos |d 2011 |g 19(2020), 4 vom: 21. Dez., Seite 291-299 |w (DE-627)NLM24161676X |x 1735-0344 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2020 |g number:4 |g day:21 |g month:12 |g pages:291-299 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2020 |e 4 |b 21 |c 12 |h 291-299 | ||